Seres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.com

Seres Therapeutics (NASDAQ:MCRB) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Tuesday.

Other research analysts have also recently issued reports about the company. JPMorgan Chase & Co. cut Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Thursday, October 24th. Chardan Capital reissued a “buy” rating and issued a $1.25 price objective on shares of Seres Therapeutics in a report on Wednesday, November 13th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $10.00 target price on shares of Seres Therapeutics in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat, Seres Therapeutics presently has an average rating of “Hold” and an average target price of $5.08.

Seres Therapeutics Stock Performance

Shares of NASDAQ MCRB traded up $0.11 during midday trading on Tuesday, hitting $0.69. 4,379,300 shares of the stock traded hands, compared to its average volume of 4,322,203. Seres Therapeutics has a one year low of $0.54 and a one year high of $2.05. The firm has a market capitalization of $117.54 million, a P/E ratio of -2.99 and a beta of 2.06. The firm has a 50-day moving average of $0.83 and a two-hundred day moving average of $0.91.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Providence Wealth Advisors LLC raised its stake in Seres Therapeutics by 49.5% during the 2nd quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 25,250 shares during the period. Point72 DIFC Ltd bought a new stake in shares of Seres Therapeutics during the 2nd quarter valued at $64,000. Virtu Financial LLC purchased a new position in shares of Seres Therapeutics during the 1st quarter valued at $73,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Seres Therapeutics in the 2nd quarter worth $92,000. Finally, State Street Corp increased its stake in Seres Therapeutics by 12.9% in the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock worth $363,000 after buying an additional 43,700 shares in the last quarter. 59.34% of the stock is owned by hedge funds and other institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.